Valneva Shares Slump After FDA Postpones Chikungunya Vaccine Review Date
By Maitane Sardon
Shares in Valneva plunged in early trading Monday after the French biotech company said the U.S. Food and Drug Administration has delayed the target date for completing the regulatory review of the marketing application for its Chikungunya vaccine candidate.
At 0713 GMT, shares were down 8.5% at EUR6.14 after falling as much as 12% at open.
The review is now set for the end of November and not the end of August as initially planned, Valneva said.
The FDA extended the date to allow sufficient time to align and agree on the Phase 4 trial program required under the accelerated approval pathway, the company said.
The agency hasn't requested any additional clinical data for the approval process, Valneva added.
Write to Maitane Sardon at maitane.sardon@wsj.com
(END) Dow Jones Newswires
August 14, 2023 03:40 ET (07:40 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom